Eli Lilly launches program to boost employer coverage of obesity drugs
Eli Lilly on Thursday launched a new program designed to help more employers cover obesity drugs in the…
Why Novo Nordisk’s Ireland expansion is key to fighting off Eli Lilly
Novo Nordisk is investing 432 million euros ($506 million) in a facility in Ireland as it expands its…
These 4 charts show the scale of Novo Nordisk’s woes
Novo Nordisk was the first company to make a GLP-1 drug for weight loss and became Europe’s most…
What’s next for Novo Nordisk’s obesity drug CagriSema
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news…
Eli Lilly launches Zepbound obesity drug pen with one month of doses
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March…
Thursday's big stock stories: What’s likely to move the market in the next trading session – CNBC
Thursday’s big stock stories: What’s likely to move the market in the next trading session CNBCJ Balvin & More…